10 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
transparency for drug pricing, modify the government program reimbursement methodologies, and provide additional ways for the government to attempt … . In addition, in August 2022, the Inflation Reduction Act of 2022 implemented substantial changes to the Medicare program, including drug pricing reforms
ARS
2022 FY
CRBU
Caribou Biosciences Inc
28 Apr 23
Annual report to shareholders
12:00am
transparency for drug pricing, modify the government program reimbursement methodologies, and provide additional ways for the government to attempt … ; expansion of the list of covered entities eligible to participate in the 340B drug pricing program; expansion of eligibility criteria for Medicaid
10-K
2021 FY
CRBU
Caribou Biosciences Inc
21 Mar 22
Annual report
4:19pm
in the 340B drug pricing program;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage … pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall
424B4
CRBU
Caribou Biosciences Inc
23 Jul 21
Prospectus supplement with pricing info
4:24pm
to the federal government; (iv) expanded the list of covered entities eligible to participate in the 340B drug pricing program; (v) established a new … , state, and foreign legislative and regulatory developments are likely and we expect ongoing initiatives to increase pressure on drug pricing
S-1/A
1kjp5mh 73k8l
19 Jul 21
IPO registration (amended)
6:09am
S-1
cvaqwkb3fd8sq4724ba8
1 Jul 21
IPO registration
4:05pm
DRS/A
wy8djpuy2tf81j0
11 Jun 21
Draft registration statement (amended)
12:00am
DRS
411ftgnaci
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next